Program
Cannabidiol
Also written as “GWP42003-P”, “Cannabidiol Oral Solution” and “CBD”.
Its studies are mostly in Epilepsy · Lennox Gastaut Syndrome · Epilepsies, Myoclonic · Seizures · Spasms, Infantile, led by 16 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 315 open or running | phase 4since Oct 17, 2019 | Oct 7, 2010 | Aug 1, 2027phase 4 · NCT05044819 |
| INSYS Therapeutics | 50 open or running | phase 3since Dec 12, 2014 | Dec 12, 2014 | none ahead |
| Radius Pharmaceuticals | 50 open or running | phase 3since Jan 26, 2018 | Jul 22, 2016 | none ahead |
| Cardiol Therapeutics | 41 open or running | phase 3since Nov 2, 2020 | Nov 2, 2020 | none ahead |
| Pure Green | 40 open or running | phase 2since Sep 10, 2019 | Sep 10, 2019 | none ahead |
| Canopy Growth | 30 open or running | phase 2since Aug 29, 2019 | Aug 29, 2019 | none ahead |
| Botanix Pharmaceuticals | 20 open or running | phase 2since Jun 19, 2018 | Jun 19, 2018 | none ahead |
| Stero Biotechs | 20 open or running | phase 2since Mar 18, 2019 | Mar 18, 2019 | none ahead |
| Avecho Biotechnology | 11 open or running | phase 3since Apr 23, 2023 | Apr 23, 2023 | Sep 30, 2027phase 3 · NCT05840822 |
| bod-australia | 10 open or running | phase 2since Dec 20, 2021 | Dec 20, 2021 | none ahead |
| dsm-firmenich | 10 open or running | phase 1since Aug 20, 2024 | Aug 20, 2024 | none ahead |
| empowerpharm-inc | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
| kalytera-therapeutics-israel-ltd | 10 open or running | phase 2since Feb 10, 2019 | Feb 10, 2019 | none ahead |
| laboratorio-elea-phoenix-s-a | 11 open or running | phase 2since Sep 30, 2024 | Sep 30, 2024 | none ahead |
| pure-green-pharmaceuticals-inc | 10 open or running | phase 2since Mar 2, 2023 | Mar 2, 2023 | none ahead |
| Tiamat Australia Pty | 10 open or running | phase 1since Feb 14, 2025 | Feb 14, 2025 | none ahead |
Also a collaborator on its studies: jazz-pharmaceuticals-research-uk-limited and benuvia-therapeutics-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Mar 17, 2014.
- Mar 21, 2022Phase 1 study in Bone Diseases, MetabolicCanopy Growth · NCT05317013 · 2 enrolled · United States
- Aug 8, 2022Phase 2 study in PericarditisCardiol Therapeutics · NCT05494788 · 27 enrolled · United States
- Oct 26, 2022empowerpharm-inc's first study: phase 2 study in Phobia, SocialNew to empowerpharm-incempowerpharm-inc · NCT05600114 · 239 enrolled · United States
- Dec 24, 2022Phase 2 study in Menstrual DiscomfortCanopy Growth · NCT05679830 · 33 enrolled · United States
- Mar 2, 2023pure-green-pharmaceuticals-inc's first study: phase 2 study in Diabetic Peripheral Neuropathic PainNew to pure-green-pharmaceuticals-incpure-green-pharmaceuticals-inc · NCT05766969 · 52 enrolled · United States
- Apr 23, 2023Avecho Biotechnology's first study: phase 3 study in Sleep Initiation and Maintenance DisordersNew to Avecho BiotechnologyAvecho Biotechnology · NCT05840822 · 519 enrolled · Australia
- May 9, 2023Phase 4 study in SeizuresJazz Pharmaceuticals · NCT05864846 · 79 enrolled · United States, Canada, Poland and more
- Aug 20, 2024dsm-firmenich's first study: phase 1 study in CBD PharmacokineticsNew to dsm-firmenichdsm-firmenich · NCT06578455 · 32 enrolled · Canada
- Sep 30, 2024laboratorio-elea-phoenix-s-a's first study: phase 2 study in Parkinson DiseaseNew to laboratorio-elea-phoenix-s-alaboratorio-elea-phoenix-s-a · NCT06629389 · 88 planned · Argentina
- Nov 25, 2024Phase 3 study in PericarditisCardiol Therapeutics · NCT06708299 · 110 planned · United States, Canada, Greece and more
- Feb 14, 2025Tiamat Australia Pty's first study: phase 1 study in PharmacokineticsNew to Tiamat Australia PtyTiamat Australia Pty · NCT06854783 · 20 enrolled · Australia
- Nov 14, 2025Phase 1 study in SeizuresJazz Pharmaceuticals · NCT07233239 · 100 planned · United States
- Jul 20, 20262 phase 3 studiesJazz Pharmaceuticals · NCT07723976, NCT07723963
- Jul 22, 2026Phase 4 study in Lennox Gastaut SyndromeJazz Pharmaceuticals · NCT07728097 · 40 planned · United States
Ahead
- Aug 1, 2027Primary completion: phase 4 study in Lennox Gastaut SyndromeJazz Pharmaceuticals · NCT05044819
- Sep 30, 2027Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersAvecho Biotechnology · NCT05840822
- Nov 29, 2027Primary completion: phase 1 study in SeizuresJazz Pharmaceuticals · NCT07233239
- Aug 1, 2028Primary completion: phase 3 study in Myoclonic Epilepsy, JuvenileJazz Pharmaceuticals · NCT07723963
TargetBeta
“Cannabinoid CB1 receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rimonabantrule | Sanofi | phase 3 | 38 |
| Dronabinolrule | Jazz Pharmaceuticals | phase 3 | 20 |
| CRB-913rule | corbus-pharmaceuticals-inc | phase 1 | 1 |
Studies
The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07728097Lennox Gastaut Syndrome · United States | 4 | Not yet recruiting | Jazz Pharmaceuticals | Dec 28, 2028 | 40 |
| NCT07723976Developmental and Epileptic Encephalopathy (DEE) | 3 | Not yet recruiting | Jazz Pharmaceuticals | Sep 4, 2029 | 120 |
| NCT07723963Myoclonic Epilepsy, Juvenile · United States | 3 | Recruiting | Jazz Pharmaceuticals | Aug 1, 2028 | 260 |
| NCT07233239Seizures · United States | 1 | Recruiting | Jazz Pharmaceuticals | Nov 29, 2027 | 100 |
| NCT06854783Pharmacokinetics · Australia | 1 | Completed | Tiamat Australia Pty | Oct 1, 2025 | 20 |
| NCT06708299Pericarditis · United States, Canada, Greece and more | 3 | Recruiting | Cardiol Therapeutics | Sep 21, 2026 | 110 |
| NCT06629389Parkinson Disease · Argentina | 2 | Recruiting | laboratorio-elea-phoenix-s-a | Nov 2025 | 88 |
| NCT06578455CBD Pharmacokinetics · Canada | 1 | Completed | dsm-firmenich | Nov 20, 2024 | 32 |
| NCT05864846Seizures · United States, Canada, Poland and more | 4 | Completed | Jazz Pharmaceuticals | Apr 6, 2026 | 79 |
| NCT05840822Sleep Initiation and Maintenance Disorders · Australia | 3 | Active, not recruiting | Avecho Biotechnology | Sep 30, 2027 | 519 |
| NCT05766969Diabetic Peripheral Neuropathic Pain · United States | 2 | UNKNOWN | pure-green-pharmaceuticals-inc | Dec 5, 2023 | 52 |
| NCT05679830Menstrual Discomfort · United States | 2 | Completed | Canopy Growth | Sep 23, 2021 | 33 |
| NCT05600114Phobia, Social · United States | 2 | Completed | empowerpharm-inc | Dec 13, 2023 | 239 |
| NCT05494788Pericarditis · United States | 2 | Completed | Cardiol Therapeutics | Jun 15, 2024 | 27 |
| NCT05317013Bone Diseases, Metabolic · United States | 1 | Terminated | Canopy Growth | Sep 22, 2022 | 2 |
| NCT05288283Epilepsy · United States, Italy | 3 | Terminated | Jazz Pharmaceuticals | Sep 28, 2023 | 3 |
| NCT05253417Parasomnias · Australia | 2 | Completed | bod-australia | Jul 7, 2023 | 208 |
| NCT05180240Acute Myocarditis · United States, Brazil, Canada and more | 2 | Completed | Cardiol Therapeutics | Jan 31, 2025 | 109 |
| NCT05044819Lennox Gastaut Syndrome · United States | 4 | Active, not recruiting | Jazz Pharmaceuticals | Aug 1, 2027 | 154 |
| NCT04992962Osteoarthritis, Knee · United States | 2 | UNKNOWN | Pure Green | Oct 30, 2021 | 66 |
| NCT04745026Autism Spectrum Disorder · United States, Australia, Canada and more | 2 | Completed | Jazz Pharmaceuticals | Dec 21, 2023 | 103 |
| NCT04679545Diabetic Peripheral Neuropathic Pain · United States | 2 | UNKNOWN | Pure Green | Mar 1, 2021 | 50 |
| NCT04615949COVID-19 · United States, Brazil, Mexico | 3 | Terminated | Cardiol Therapeutics | Nov 30, 2022 | 90 |
| NCT04485104Epilepsy · United States, Italy, Spain | 3 | Terminated | Jazz Pharmaceuticals | Jan 28, 2025 | 3 |
| NCT04421456Schizophrenia · United States, Poland, Serbia and more | 2 | Terminated | Jazz Pharmaceuticals | Mar 16, 2022 | 95 |
| NCT04252586Rett Syndrome · United States, Australia, Canada and more | 3 | Terminated | Jazz Pharmaceuticals | Jun 9, 2021 | 21 |
| NCT04439955Chronic Urticaria · Israel | 2 | Completed | Stero Biotechs | Jul 30, 2021 | 15 |
| NCT04193631Musculoskeletal Pain · United States | 1 | Completed | Pure Green | Dec 9, 2019 | 16 |
| NCT04133480Lennox Gastaut Syndrome | 4 | Withdrawn | Jazz Pharmaceuticals | Dec 2021 | 0 |
| NCT04088929Diabetic Neuropathies · United States | 2 | Completed | Pure Green | Nov 22, 2019 | 32 |
| NCT04086342Phobia, Social · Canada | 2 | Withdrawn | Canopy Growth | Jan 26, 2021 | 0 |
| NCT04129489Hepatitis, Autoimmune · Israel | 2 | Terminated | Stero Biotechs | Mar 1, 2020 | 2 |
| NCT03848832Rett Syndrome · United States, Italy, Spain and more | 3 | Terminated | Jazz Pharmaceuticals | Jan 21, 2021 | 29 |
| NCT03840512Prevention aGVHD · Australia, Israel | 2 | UNKNOWN | kalytera-therapeutics-israel-ltd | Nov 15, 2022 | 36 |
| NCT03824405Dermatitis, Atopic · United States, Australia, New Zealand | 2 | Completed | Botanix Pharmaceuticals | Jan 27, 2020 | 200 |
| NCT03573518Acne Vulgaris · United States, Australia | 2 | Completed | Botanix Pharmaceuticals | Aug 16, 2019 | 368 |
| NCT03458416Prader-Willi Syndrome · United States | 2 | Terminated | Radius Pharmaceuticals | Jul 31, 2019 | 2 |
| NCT03421496Spasms, Infantile · United States | 3 | Terminated | Radius Pharmaceuticals | May 29, 2019 | 2 |
| NCT03355300Epilepsy, Absence · United States | 2 | Terminated | Radius Pharmaceuticals | Jun 24, 2019 | 11 |
| NCT03336242Epilepsy, Absence · United States | 2 | Terminated | Radius Pharmaceuticals | May 15, 2019 | 20 |
| NCT02954887Spasms, Infantile · United States, Poland | 3 | Completed | Jazz Pharmaceuticals | Jun 13, 2019 | 9 |
| NCT02953548Spasms, Infantile · United States, Poland | 3 | Completed | Jazz Pharmaceuticals | May 7, 2018 | 9 |
| NCT02844933Prader-Willi Syndrome · United States | 2 | Terminated | Radius Pharmaceuticals | Jul 17, 2019 | 7 |
| NCT02607904Epilepsy · Netherlands, Spain, Sweden | 2 | Completed | Jazz Pharmaceuticals | May 27, 2019 | 30 |
| NCT02607891Epilepsy · Netherlands, Spain, Sweden | 2 | Completed | Jazz Pharmaceuticals | Sep 11, 2018 | 35 |
| NCT02565108Epilepsy · Spain, United Kingdom | 2 | Completed | Jazz Pharmaceuticals | Jul 21, 2016 | 20 |
| NCT02564952Epilepsy · Spain, United Kingdom | 2 | Completed | Jazz Pharmaceuticals | Jun 7, 2017 | 18 |
| NCT02551731Spasms, Infantile · United States | 2 | Terminated | INSYS Therapeutics | Sep 6, 2016 | 9 |
| NCT02544763Tuberous Sclerosis · United States, Australia, Netherlands and more | 3 | Completed | Jazz Pharmaceuticals | Jan 22, 2019 | 224 |
| NCT02544750Tuberous Sclerosis · United States | 3 | Completed | Jazz Pharmaceuticals | Jun 11, 2021 | 199 |
| NCT02324673Seizures · United States | 2 | Completed | INSYS Therapeutics | May 9, 2016 | 61 |
| NCT02318602Seizures · United States | 3 | Completed | INSYS Therapeutics | Jun 22, 2017 | 52 |
| NCT02318563Epilepsies, Myoclonic | 3 | Withdrawn | INSYS Therapeutics | Jun 17, 2018 | 0 |
| NCT02318537Lennox Gastaut Syndrome | 3 | Withdrawn | INSYS Therapeutics | Jun 30, 2018 | 0 |
| NCT02224703Epilepsy · United States, Australia, Israel and more | 3 | Completed | Jazz Pharmaceuticals | Apr 9, 2018 | 199 |
| NCT02224690Epilepsy · United States, Netherlands, Poland | 3 | Completed | Jazz Pharmaceuticals | Mar 18, 2016 | 171 |
| NCT02224573Epilepsy | 3 | Completed | Jazz Pharmaceuticals | Sep 24, 2020 | 681 |
| NCT02224560Epilepsy · United States, France, Spain and more | 3 | Completed | Jazz Pharmaceuticals | May 19, 2016 | 225 |
| NCT02091375Epilepsy · United States, France, Poland and more | 3 | Completed | Jazz Pharmaceuticals | Nov 26, 2015 | 120 |
| NCT02091206Epilepsy · United States, United Kingdom | 2 | Completed | Jazz Pharmaceuticals | Mar 9, 2015 | 34 |
How it is read
Names in the registry
- “GWP42003-P”, 17 entries
- “Cannabidiol Oral Solution”, 10 entries
- “Cannabidiol”, 7 entries
- “CBD”, 5 entries
- “GWP42003”, 4 entries
Codes read as this program: JZP926.
Conditions, from the studies’ own filings
- Epilepsy, 7 studies
- Lennox Gastaut Syndrome, 6 studies
- Epilepsies, Myoclonic, 5 studies
- Seizures, 4 studies
- Spasms, Infantile, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.